Structure based drug design of crizotinib (PF-02341066), a potent and selective dual inhibitor of mesenchymal–epithelial transition factor (c-MET) kinase and …

JJ Cui, M Tran-Dubé, H Shen, M Nambu…

Index: Journal of Medicinal Chemistry, , vol. 54, # 18 p. 6342 - 6363

Full Text: HTML

Citation Number: 346

Abstract

... Journal of Medicinal Chemistry. ... optimization of the lead series generated the clinical candidate crizotinib (PF-02341066), which demonstrated potent in vitro and in vivo c-MET kinase and ALK inhibition, effective tumor growth inhibition, and good pharmaceutical properties. ...